Currently available drugs do not work in the same manner for every individual. Pharmacogenomics is a study of how genes affect an individual’s response to medicines. It utilizes one’s information associated to a genome to pick a suitable treatment plan.
Theranostics is a shift from traditional medication to a more modern, personalized, and precision-driven approach to medication. It is a field of medicine that offers definite targeted treatment based on a targeted diagnostic examination. Theranostics can make use of a biological pathway in the human body for obtaining diagnostic imageries and distributing a therapeutic dose of radiation to the patient.
Companion diagnostics (CDx) is used to determine the aptness of patients for personalized or targeted forms of therapy. It can identify who is most likely to benefit from or have an adverse response to a specific therapeutic product.
Companion Diagnostic Assay to Treat Cancer
FoundationFocus CDxBRCA is the first FDA-approved companion diagnostic assay. This product is used in ovarian cancer care with Rubraca (rucaparib), a remedy developed by Clovis Oncology, Inc. It is a poly (ADP-ribose) polymerase (PARP) inhibitor therapy for BRCA-mutated ovarian cancer.
It examines the ovarian cancer tumor tissue for detecting germline (inherited) as well as somatic (acquired) BRCA1/2 mutation types, which are allied with response to PARP inhibitor therapy.
Agilent Technologies Introduces “Most Rapid Hybridization” Solution on the Market
In July 2017, Agilent Technologies Inc. launched a new product called “Agilent SureSelectXT HS”. It is a next-generation sequencing (NGS) library preparation solution. This high sensitivity solution is used in research labs for sequencing DNA from FFPE samples, which may have degraded with time. It is reportedly the most rapid hybridization on the market.
Market Overview
According to Grand View Research, Inc., the global pharmacogenomics technology (theranostics & companion diagnostics) market is set to achieve around USD 18.3 billion by 2025.
Oncology therapeutics is predicted to gain the largest revenue share due to advanced theranostics techniques available in the market. Next-generation sequencing (NGS)-based clinical trial assay and companion diagnostics is anticipated to boost the market.
The North America market has been the top regional segment in the past owing to existence of developed companies. Asia Pacific is projected to show the fastest growth during the forecast period.
Key companies operating in the market include GE Healthcare, Agilent Technologies, Foundation Medicine, Leica Biosystems Nussloch GmBH, and Qiagen NV.
In-Depth research report on Pharmacogenomics Technology (Theranostics & CDx) Market:
No comments:
Post a Comment